KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

West Pharmaceutical Services (WST) Assets (2016 - 2025)

Historic Assets for West Pharmaceutical Services (WST) over the last 17 years, with Q3 2025 value amounting to $4.1 billion.

  • West Pharmaceutical Services' Assets rose 1171.94% to $4.1 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $4.1 billion, marking a year-over-year increase of 1171.94%. This contributed to the annual value of $3.6 billion for FY2024, which is 485.96% down from last year.
  • Per West Pharmaceutical Services' latest filing, its Assets stood at $4.1 billion for Q3 2025, which was up 1171.94% from $4.0 billion recorded in Q2 2025.
  • Over the past 5 years, West Pharmaceutical Services' Assets peaked at $4.1 billion during Q3 2025, and registered a low of $2.7 billion during Q1 2021.
  • Its 5-year average for Assets is $3.5 billion, with a median of $3.6 billion in 2022.
  • As far as peak fluctuations go, West Pharmaceutical Services' Assets skyrocketed by 2262.26% in 2021, and later tumbled by 491.06% in 2024.
  • West Pharmaceutical Services' Assets (Quarter) stood at $3.3 billion in 2021, then rose by 9.14% to $3.6 billion in 2022, then grew by 5.88% to $3.8 billion in 2023, then fell by 4.86% to $3.6 billion in 2024, then rose by 12.69% to $4.1 billion in 2025.
  • Its last three reported values are $4.1 billion in Q3 2025, $4.0 billion for Q2 2025, and $3.6 billion during Q1 2025.